Join us in exploring the future of healthcare with our latest blog post on the promise of cell therapy. Discover why this revolutionary approach is capturing global attention and how Precision for Medicine is shaping its evolution: https://hubs.li/Q02FfYG20 #CellTherapy #HealthcareInvesting #PrecisionMedicine
Claritas Rx
Data Infrastructure and Analytics
South San Francisco, California 5,575 followers
Delivering actionable information tailored to your unique needs is what sets us apart.
About us
Claritas Rx started with a simple vision: to tangibly improve how biopharmaceutical manufacturers understand their specialty product performance in the marketplace. Since then, Claritas Rx has grown from a small channel data consultancy to become a pioneer in patient-level data integration and analytics for the biopharmaceutical industry. Today, our customers range from small biotechnology companies launching their first specialty product to large global manufacturers with a strong portfolio of specialty products.
- Website
-
http://www.claritasrx.com
External link for Claritas Rx
- Industry
- Data Infrastructure and Analytics
- Company size
- 51-200 employees
- Headquarters
- South San Francisco, California
- Type
- Privately Held
- Founded
- 2011
- Specialties
- patient intervention and patient services support suite
Locations
-
Primary
Get directions
611 Gateway Boulevard
Suite 201
South San Francisco, California 94080, US
Employees at Claritas Rx
Updates
-
AstraZeneca's Calquence is redefining first-line treatment for Mantle Cell Lymphoma, showing promising results in reducing disease progression by 27%. Learn more about this breakthrough in our latest article: https://hubs.li/Q02Df6n30 #Biopharma #Innovation #Healthcare
Breakthrough in Mantle Cell Lymphoma Treatment AstraZeneca's Calquence Sets New Standard
claritasrx.com
-
The FDA's new draft guide could revolutionize the approval process for cell and gene therapies. Find out how this could speed up the development of life-saving treatments: https://hubs.li/Q02Cn5LQ0
FDA Introduces Draft Guidance for Platform Technologies: A New Pathway to Fast-Track Cell and Gene Therapy Approvals
https://www.claritasrx.com
-
The FDA's approval of Amgen's Bkemv as an interchangeable biosimilar for Soliris marks a significant advancement in accessible treatments for rare blood diseases. Learn more about this groundbreaking development: https://hubs.li/Q02By-100
Innovations in Biopharma: FDA Approves Amgen's First Interchangeable Biosimilar
-
AstraZeneca latest strategic blueprint reveals a goal of hitting $80 billion in revenue by 2030, while also introducing 20 novel drugs. This determination towards novelty emphasizes their crucial contribution in crafting the upcoming era of healthcare. #AstraZeneca #HealthcareInnovation #Pharmaceuticals https://hubs.li/Q02zyzZ50
Entering a New Era of Growth: AstraZeneca Targets $80 Billion Revenue by 2030
https://www.claritasrx.com
-
Discover how AI can revolutionize your market access and commercial strategies by predicting patient trends! Our latest article in the PMSA Journal dives deep into actionable insights tailored for biopharma executives. Don't miss out on this cutting-edge research. PMSA Journal Spring 2024, Pg 113: https://hubs.li/Q02zjC_60 #Biopharma #AI #MarketAccess
-
Exciting strides in asthma treatment as GSK's Depemokimab emerges victorious in two pivotal Phase 3 trials! These results mark a significant advancement in the quest for more effective and convenient treatments for severe asthma. With its demonstrated efficacy in reducing annual asthma attacks and the added convenience of six-month dosing intervals, Depemokimab holds promise for transforming the lives of those living with this chronic condition. As GSK progresses towards regulatory approval and further studies, the potential for Depemokimab to become a game-changer in the field of respiratory medicine becomes increasingly apparent. #AsthmaTreatment #Depemokimab #GSK #RespiratoryMedicine https://hubs.li/Q02yTTJy0
An Exciting Leap in Asthma Treatment: GSK's New Experimental Drug Clears Two Phase 3 Trials
https://www.claritasrx.com
-
Sanofi, OpenAI, and Formation Bio have announced a unique partnership aiming to develop AI-powered drug R&D software. This collaboration combines Sanofi's data, OpenAI's AI proficiency, and Formation Bio's engineering resources. The partnership aims to create custom solutions to streamline drug development and build large language models. Sanofi’s CEO, Paul Hudson, emphasized the commitment to transforming into an AI-fueled pharma company. With similar partnerships emerging, AI is poised to revolutionize biopharma. #PharmaTech #AIinHealthcare #DrugDevelopment https://hubs.li/Q02y98b10 🎓 Join us for a webinar on AI: “Deploying AI/Machine Learning to Forecast Patient Treatment Dropoff Daily” presented by Claritas Rx on May 23rd. https://lnkd.in/gJ5sE6AK
Big Pharma and Tech Combine Power: Unlocking AI's Potential to Revolutionize Drug Development
https://www.claritasrx.com
-
Walgreens expands services with gene and cell therapies, marking a major breakthrough in healthcare. Learn more about this innovative move and what it means for you. https://hubs.ly/Q02xrqxn0 #Walgreens #HealthcareInnovation #GeneTherapy #CellTherapy #HealthcareForAll
Pioneering a New Chapter in Healthcare: Walgreens Diversifies into Gene and Cell Therapies
https://www.claritasrx.com
-
Claritas Rx reposted this
NASP members join us Thursday, May 23, at 1PM ET for "Deploying AI / Machine Learning to Forecast Patient Treatment Dropoff Daily" presented by Claritas Rx. Members register here: https://bit.ly/4a4UdjD Not a member? Join TODAY! https://bit.ly/3Y0xMYo #ThisIsNASP #specialtypharmacy #AI #machinelearning
-